GlassScriptPhysician profile
Michael Joseph Zappulla
NPI 1639686611
$1,576.73
in general payments reported to CMS, 2019-2025
23 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $540 · 2023: $486 · 2024: $340 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,036.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $447.79 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $269.26 | 2022-2024 | Eterna |
| Collegium Pharmaceutical, INC. | $120.42 | 2022-2024 | Belbuca, Xtampza |
| Averitas Pharma INC. | $105.40 | 2023 | Qutenza |
| Scilex Pharmaceuticals INC. | $95.54 | 2022-2023 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.93 | 2024 | Relistor |
| Azurity Pharmaceuticals, INC. | $62.34 | 2023-2024 | Horizant, Horizant |
| Valinor Pharma, LLC | $49.93 | 2023-2024 | Movantik |
| Boston Scientific Corporation | $32.13 | 2024 | Intracept |
| Abbvie INC. | $31.87 | 2022 | |
| Spr Therapeutics, INC | $29.86 | 2023 | Sprint Pns System |
| Novo Nordisk INC | $29.38 | 2025 | Rybelsus, Ozempic |
| Edwards Lifesciences Corporation | $27.80 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Axsome Therapeutics, INC. | $21.07 | 2025 | Auvelity |
| Ibsa Pharma INC. | $20.88 | 2023 | Tirosint, Licart |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.53 | 2025 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $20.03 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $17.99 | 2025 | Keveyis |
| Novartis Pharmaceuticals Corporation | $17.74 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.25 | 2022 | |
| Nevro Corp. | $15.70 | 2024 | Senza |
| Exact Sciences Corporation | $15.46 | 2025 | Cologuard Collection Kit |
| Painteq LLC | $15.43 | 2024 | Painteq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zappulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.